These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Comparison of the effects of human recombinant insulin-like growth factor I and insulin on plasma amino acid concentrations and leucine kinetics in humans.
    Author: Giordano M, Castellino P, Carroll CA, DeFronzo RA.
    Journal: Diabetologia; 1995 Jun; 38(6):732-8. PubMed ID: 7672498.
    Abstract:
    We examined the effects of recombinant human insulin-like growth factor I (IGF-I) and insulin on the plasma amino acid (AA) profile and leucine kinetics in eight normal subjects. IGF-I was infused at 52 pmol.kg-1.min-1, in combination with prime-continuous [1-14C] leucine infusion, to obtain steady-state plasma concentrations of total (54 +/- 3 nmol/l) and free (7.3 +/- 1 nmol/l) IGF-I (study 1). In response to IGF-I, plasma AA levels declined by 37 +/- 3% (1975 +/- 198 to 1368 +/- 120 mumol/l) and total branched chain amino acids (BCAA) declined by 34 +/- 3% (390 +/- 21 to 256 +/- 13 mumol/l). This hypoaminoacidaemic effect was associated with a decline in endogenous leucine flux of 17 +/- 2% (1.88 +/- 0.05 to 1.57 +/- 0.04 mumol.kg-1.min-1) and leucine oxidation of 17 +/- 1% (0.31 +/- 0.02 vs 0.26 +/- 0.02 mumol.kg-1.min-1) (both p < 0.01 vs basal). The same subjects underwent a second study (study 2) in which insulin was infused at 6.22 pmol.kg-1.min-1 to obtain a steady-state plasma insulin concentration of 530 +/- 25 pmol/l while maintaining euglycaemia. The infusion rate was designed to match the declines in plasma BCAA levels and leucine turnover observed during IGF-I infusion. The rates of glucose infusion necessary to maintain euglycaemia during IGF-I and insulin infusion were 4.9 +/- 1.0 and 7.8 +/- 0.6 mg.kg-1.min-1, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]